A study in the Journal of the American Heart Association found that sodium-glucose cotransporter 2 inhibitors could help protect against major adverse cardiac events like heart failure and cardiovascular death, as well as death from any cause, among individuals with type 2 diabetes. Researchers evaluated data from 38,723 patients with type 2 diabetes and wrote that "SGLT2 inhibition should be considered in all patients with type 2 diabetes mellitus and elevated risk of cardiovascular disease, even in the absence of established disease."
SGLT2 inhibitors tied to reduced CVD risk in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.